^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    2d
    CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (clinicaltrials.gov)
    P1, N=24, Suspended, Medical College of Wisconsin | Recruiting --> Suspended
    Trial suspension
    |
    CD20 positive
    |
    CAR-20/19-T Cells
    8d
    ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Shanghai AbelZeta Ltd. | Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    prizloncabtagene autoleucel (JNJ-4496)
    21d
    Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. (PubMed, RMD Open)
    We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.
    Journal • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    24d
    A Study of LCAR-AIO in Subjects with Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    LCAR-AIO
    1m
    Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. (PubMed, Front Immunol)
    In conclusion, the CliniMACS Prodigy® platform is well suited for decentralized POC manufacturing of anti-CD20 CAR T cells and may be likewise applicable for the rapid and automated manufacturing of CAR T cells directed against other targets. https://clinicaltrials.gov/study/NCT03893019?cond=Melanoma&term=NCT03893019&rank=1, identifier NCT03893019.
    Journal • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    MB-CART20.1
    2ms
    CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=4, Terminated, Medical College of Wisconsin | All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR20.19.22 T
    2ms
    Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
    |
    CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab)
    3ms
    INVISE: Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (clinicaltrials.gov)
    P1, N=30, Recruiting, Interius BioTherapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, RenJi Hospital
    New P1 trial
    3ms
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, Janssen Research & Development, LLC | N=92 --> 20
    Enrollment change • CAR T-Cell Therapy
    |
    JNJ-9530
    3ms
    INVISE: Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Interius BioTherapeutics Inc.
    New P1 trial
    4ms
    Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, Shanghai First Song Biotechnology Co., LTD
    New P1 trial • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cyclophosphamide • fludarabine IV
    4ms
    An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, Fudan University
    New P1 trial
    |
    cyclophosphamide
    4ms
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=36, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    cyclophosphamide
    4ms
    MB106-CD20-001: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (clinicaltrials.gov)
    P1/2, N=20, Terminated, Mustang Bio | N=287 --> 20 | Trial completion date: Sep 2026 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Apr 2024; Business reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MB-106
    4ms
    Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (clinicaltrials.gov)
    P=N/A, N=3, Terminated, Mustang Bio | N=331 --> 3 | Trial completion date: Jul 2041 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Apr 2041 --> Apr 2024; Business Reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    MB-106 • MB-102
    4ms
    DALY 2-EU: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (clinicaltrials.gov)
    P2, N=168, Active, not recruiting, Miltenyi Biomedicine GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
    4ms
    Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (clinicaltrials.gov)
    P1/2, N=12, Completed, Miltenyi Biomedicine GmbH | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2024
    Trial completion • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    4ms
    LONGSAFE: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Miltenyi Biomedicine GmbH
    New trial • Gene therapy
    |
    MB-CART 19.1 • MB-CART20.1 • zamtocabtagene autoleucel (MB-CART2019.1)
    4ms
    DALY PED: Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P2 trial
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    4ms
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=36, Enrolling by invitation, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    cyclophosphamide
    5ms
    A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov)
    P1, N=21, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2031 --> Aug 2031 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    5ms
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P1 trial
    |
    cyclophosphamide
    5ms
    A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Mar 2024
    Enrollment closed • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cyclophosphamide • fludarabine IV • MB-106
    5ms
    PRO00037171: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Medical College of Wisconsin | Trial completion date: Dec 2025 --> Jan 2025 | Trial primary completion date: Dec 2025 --> Jan 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR-20/19-T Cells
    5ms
    A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Shanghai Cell Therapy Group Co.,Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    cyclophosphamide
    6ms
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=33, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide
    6ms
    Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=36, Recruiting, Sumithira Vasu | Trial completion date: Dec 2024 --> Jul 2026 | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD20 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
    6ms
    A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov)
    P1, N=21, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Medical College of Wisconsin | Trial completion date: Feb 2025 --> Jul 2027 | Initiation date: Apr 2024 --> Jul 2024 | Trial primary completion date: Nov 2024 --> Jul 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy
    |
    Jaypirca (pirtobrutinib) • CAR-20/19-T Cells
    6ms
    MB-CART20.1 Melanoma (clinicaltrials.gov)
    P1, N=9, Terminated, Miltenyi Biomedicine GmbH | N=15 --> 9 | Recruiting --> Terminated; The risk-benefit assessment was not as expected.
    Enrollment change • Trial termination • Metastases
    |
    MB-CART20.1
    6ms
    Long-term Remissions Following CD20-directed Chimeric Antigen Receptor Adoptive T cell Therapy. (PubMed, Blood Cancer Discov)
    Here, we present long-term follow-up of a pilot trial testing a CD20-targeting 3rd generation CAR in patients with relapsed B-cell lymphomas following cyclophosphamide-only lymphodepletion...Correlative immunologic analyses supported this hypothesis, with evidence of new humoral and cellular anti-tumor immune responses proximal to clinical response time points. Collectively, our results suggest that CAR T cell therapy may facilitate epitope spreading and endogenous immune response formation in lymphomas.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cyclophosphamide
    6ms
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting | N=34 --> 20
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    6ms
    CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Uppsala University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cyclophosphamide • fludarabine IV • ELC-301
    7ms
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P1 trial
    |
    cyclophosphamide
    7ms
    MB-CART20.1 Lymphoma (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Nov 2022 --> Sep 2024 | Trial primary completion date: Feb 2022 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    MB-CART20.1
    7ms
    MPCT-012L: Study of IMPT-314 in R/R Aggressive B-cell NHL (clinicaltrials.gov)
    P1/2, N=150, Recruiting, ImmPACT Bio | N=100 --> 150
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    IMPT-314
    7ms
    A Phase 1 Study of ADI-001 in Lupus Nephritis (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Adicet Bio, Inc
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • ADI-001
    7ms
    An Evaluation of LY007 Cell Injection for r/r B-NHL (clinicaltrials.gov)
    P1, N=18, Recruiting, Ruijin Hospital
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression
    |
    LY007
    7ms
    GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov)
    P1, N=78, Recruiting, Adicet Bio, Inc | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • ADI-001
    7ms
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Poseida Therapeutics, Inc. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)
    8ms
    CRC-403: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov)
    P1/2, N=50, Recruiting, 2seventy bio | Trial primary completion date: Dec 2023 --> Aug 2024
    Trial primary completion date • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    bbT369